# KTTA (Pasithea Therapeutics Corp.) - SEC EDGAR Financial Statements

> Pasithea Therapeutics Corp. reported $46.49M in total assets and a net loss of $24.83M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/KTTA
- Markdown: https://convexityos.com/fundamentals/KTTA.md
- SEC CIK: 0001841330
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:04 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001841330&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$27.82M | Operating profit |
| Net Income | FY 2025 | -$24.83M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.74 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $41.22M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | $487K | $15K |
| Cost of Revenue | -- | -- | -- | $113K | $17K |
| **Gross Profit** | -- | -- | -- | $373K | -$2.2K |
| Research & Development | $7.98M | $7.20M | $8.10M | $2.67M | -- |
| Selling, General & Admin | -- | $7.05M | $7.88M | $9.92M | $4.51M |
| **Operating Income** | -$20.86M | -$14.25M | -$15.98M | -$12.59M | -$4.51M |
| **EBITDA** | -$20.19M | -$13.60M | -$15.33M | -$12.58M | -$4.51M |
| Interest Income | $327K | $423K | $415K | -- | -- |
| Interest Expense | -- | -- | -- | $102 | $508 |
| Income Before Tax | -$20.43M | -$13.90M | -$15.51M | -$11.73M | -$2.17M |
| **Net Income** | -$20.43M | -$13.90M | -$15.96M | -$13.94M | -$2.17M |
| Basic EPS | -$2.91 | -$12.69 | -$0.42 | -$1.76 | -$0.21 |
| **Diluted EPS** | -$2.91 | -$12.69 | -$0.42 | -$1.76 | -$0.21 |
| Basic Shares Outstanding | 7.0M | 1.1M | 1.2M | 1.3M | 10.4M |
| Diluted Shares Outstanding | 7.0M | 1.1M | 1.2M | 1.3M | 10.4M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $4.46M | $3.69M | $2.94M | $2.74M | $1.36M | $2.15M | $1.73M | $1.51M |
| **Operating Income** | -$6.97M | -$5.71M | -$4.88M | -$10.26M | -$3.11M | -$3.81M | -$3.68M | -$3.26M |
| **EBITDA** | -- | -- | -- | -$10.10M | -$3.09M | -$3.65M | -$3.52M | -$3.10M |
| Interest Income | $371K | $410K | $450K | $182K | $43K | $54K | $47K | $80K |
| Income Before Tax | -$6.58M | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M |
| **Net Income** | -$6.58M | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M |
| Basic EPS | -$0.20 | -$0.16 | -$0.12 | -- | -$0.41 | -$0.66 | -$1.61 | -- |
| **Diluted EPS** | -$0.20 | -$0.16 | -$0.12 | -- | -$0.41 | -$0.66 | -$1.61 | -- |
| Basic Shares Outstanding | 33.4M | 32.1M | 24.3M | -- | 7.4M | 5.6M | 2.2M | -- |
| Diluted Shares Outstanding | 33.4M | 32.1M | 24.3M | -- | 7.4M | 5.6M | 2.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $55.16M | $6.92M | $16.33M | $33.09M | $52.97M | $244K |
| **Cash & Short-Term Investments** | $55.16M | $6.92M | $16.33M | $33.09M | $52.97M | $244K |
| Other Current Assets | $388K | $143K | $105K | $263K | -- | -- |
| **Total Current Assets** | $56.46M | $7.37M | $16.69M | $34.08M | $53.30M | $248K |
| Property, Plant & Equipment, Net | -- | $122K | $141K | $125K | $20K | -- |
| Goodwill | -- | $1.26M | $1.26M | $1.26M | -- | -- |
| Intangible Assets | $2.90M | $7.31M | $7.94M | $8.57M | -- | -- |
| **Total Non-Current Assets** | $3.78M | $8.70M | $9.42M | $11.10M | $20K | $0 |
| **Total Assets** | $60.24M | $16.06M | $26.12M | $45.18M | $53.32M | $248K |
| **Total Current Liabilities** | $4.97M | $1.12M | $2.63M | $1.88M | $447K | $6.6K |
| **Total Non-Current Liabilities** | $47K | $162K | $84K | $804K | $1.45M | $0 |
| **Total Liabilities** | $5.02M | $1.28M | $2.72M | $2.68M | $1.90M | $6.6K |
| **Total Debt (incl. Leases)** | -- | -- | $82K | $504K | -- | -- |
| Common Stock | $2.3K | $139 | $104 | $130 | $18K | $15K |
| Retained Earnings | -$70.01M | -$49.58M | -$35.32M | -$19.36M | -$2.21M | -$41K |
| Accumulated Other Comp. Income | $19K | -$7.2K | -$4.7K | -$661 | -$11K | -- |
| **Total Stockholders' Equity** | $55.22M | $14.78M | $23.40M | $42.50M | $51.42M | $241K |
| Total Equity | $55.22M | $14.78M | $23.40M | $42.50M | $51.42M | $241K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $41.22M | $45.66M | $50.40M | $55.16M | $4.12M | $7.22M | $5.34M | $6.92M |
| **Cash & Short-Term Investments** | $41.22M | $45.66M | $50.40M | $55.16M | $4.12M | $7.22M | $5.34M | $6.92M |
| Other Current Assets | $35K | $23K | $400K | $388K | $20K | $118K | $162K | $143K |
| **Total Current Assets** | $43.18M | $48.24M | $52.73M | $56.46M | $5.53M | $8.64M | $6.12M | $7.37M |
| Property, Plant & Equipment, Net | -- | -- | -- | -- | -- | $114K | $118K | $122K |
| Goodwill | -- | -- | -- | -- | $1.26M | $1.26M | $1.26M | $1.26M |
| Intangible Assets | $3.31M | $3.47M | $3.62M | $2.90M | $6.84M | $7.00M | $7.15M | $7.31M |
| **Total Non-Current Assets** | $3.31M | $3.47M | $3.62M | $3.78M | $8.10M | $8.37M | $8.53M | $8.70M |
| **Total Assets** | $46.49M | $51.71M | $56.35M | $60.24M | $13.63M | $17.01M | $14.66M | $16.06M |
| **Total Current Liabilities** | $2.76M | $1.84M | $1.49M | $4.97M | $1.38M | $1.74M | $1.59M | $1.12M |
| **Total Non-Current Liabilities** | $0 | $32K | $53K | $47K | $47K | $94K | $85K | $162K |
| **Total Liabilities** | $2.76M | $1.87M | $1.54M | $5.02M | $1.42M | $1.83M | $1.68M | $1.28M |
| Common Stock | $3.3K | $3.3K | $2.5K | $2.3K | $743 | $743 | $270 | $139 |
| Retained Earnings | -$84.73M | -$78.15M | -$72.88M | -$70.01M | -$59.90M | -$56.86M | -$53.15M | -$49.58M |
| Accumulated Other Comp. Income | $48K | $9.6K | $47K | $19K | $18K | $5.6K | -- | -$7.2K |
| **Total Stockholders' Equity** | $43.73M | $49.84M | $54.80M | $55.22M | $12.21M | $15.18M | $12.98M | $14.78M |
| Total Equity | $43.73M | $49.84M | $54.80M | $55.22M | $12.21M | $15.18M | $12.98M | $14.78M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$20.43M | -$13.90M | -$15.96M | -$13.94M | -$2.17M |
| Depreciation & Amortization | $663K | $649K | $648K | $5.1K | $1.4K |
| Stock-Based Compensation | $297K | $774K | $592K | $835K | $471K |
| **Operating Cash Flow** | -$15.21M | -$13.92M | -$12.81M | -$14.56M | -$3.17M |
| Capital Expenditure | -- | -- | -$34K | -$107K | -$22K |
| **Free Cash Flow** | -- | -- | -$12.85M | -$14.67M | -$3.20M |
| Acquisitions, Net | -- | -- | -- | -$2.19M | -- |
| **Investing Cash Flow** | $11K | -- | $75K | -$2.06M | -$22K |
| Common Stock Issued | $2.08M | $4.52M | -- | -- | $1.21M |
| Share Repurchases | -- | -- | -$3.73M | -- | -- |
| **Financing Cash Flow** | $63.52M | $4.52M | -$3.73M | -$3.21M | $55.93M |
| **Net Change in Cash** | $48.34M | -$9.41M | -$16.76M | -$19.81M | $52.72M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$6.58M | -$5.27M | -$2.87M | -$10.11M | -$3.04M | -$3.72M | -$3.56M | -$3.18M |
| Depreciation & Amortization | -- | -- | -- | $158K | $24K | $161K | $162K | $162K |
| Stock-Based Compensation | $436K | $330K | $139K | $88K | $53K | $58K | $99K | $118K |
| **Operating Cash Flow** | -$4.48M | -$4.71M | -$4.79M | -$5.40M | -$2.89M | -$3.87M | -$3.06M | -$2.44M |
| Common Stock Issued | -- | -- | -- | $68K | $0 | $358K | $1.65M | -- |
| **Financing Cash Flow** | $0 | $8.5K | $750 | $56.42M | -$116K | $5.74M | $1.47M | -- |
| **Net Change in Cash** | -$4.45M | -$4.74M | -$4.76M | $51.04M | -$2.99M | $1.88M | -$1.58M | -$2.44M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Gross Margin** | -- | -- | -- | 76.7% | -14.7% |
| **Operating Margin** | -- | -- | -- | -2587.3% | -29925.7% |
| **Net Profit Margin** | -- | -- | -- | -2864.3% | -14430.5% |
| Return on Equity (ROE) | -37.0% | -94.1% | -68.2% | -32.8% | -4.2% |
| Return on Assets (ROA) | -33.9% | -86.6% | -61.1% | -30.8% | -4.1% |
| Current Ratio | 11.35x | 6.58x | 6.34x | 18.15x | 119.17x |
| Quick Ratio | 11.09x | 6.18x | 6.20x | 17.62x | 118.42x |
| Debt to Equity | -- | -- | 0.00x | 0.01x | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | +3130.4% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -56.8% | -42.7% | -36.0% | -37.0% | -110.5% | -88.7% | -104.8% | -94.1% |
| Return on Assets (ROA) | -53.4% | -41.2% | -35.0% | -33.9% | -99.0% | -79.1% | -92.8% | -86.6% |
| Current Ratio | 15.67x | 26.25x | 35.40x | 11.35x | 4.02x | 4.97x | 3.84x | 6.58x |
| Quick Ratio | 14.96x | 24.85x | 33.84x | 11.09x | 2.99x | 4.15x | 3.35x | 6.18x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
